计划性卵母细胞冷冻与体外受精联合胚胎植入前非整倍体检测的成本效果分析:基于SART数据并考虑理想家庭规模
基于SART数据构建决策树模型,比较计划性卵母细胞冷冻(OC)与高龄时行IVF/PGT-A在实现1或2个活产(LB)上的成本效果。结果显示,对于1个LB,33岁OC、43岁复苏较43岁最多3周期IVF/PGT-A降低平均总成本并提高LB概率;对于2个LB,33岁2周期OC、40岁复苏成本最低且LB概率最高。敏感性分析显示OC在广泛冷冻年龄范围内仍具成本效果。
要点
- 期望1个LB者,33岁OC、43岁复苏较43岁最多3周期IVF/PGT-A降低平均总成本并提高LB概率。
- 期望2个LB者,33岁2周期OC、40岁复苏较其他策略成本最低且实现2个LB概率最高。
- 敏感性分析显示OC在广泛冷冻年龄范围内仍具成本效果。
核心结论
- 对于计划推迟生育的患者,与较高生育年龄时行IVF/PGT-A相比,OC具有成本效果并提高实现1或2个LB的几率。
研究设计与样本
- 决策树模型,使用辅助生殖技术临床结局报告系统(SART CORS)及其他临床来源数据进行敏感性分析。
- 数据驱动的模拟队列,患者希望推迟生育且理想家庭规模为1或2个LB。
主要发现
- 期望1个LB者,33岁OC、43岁复苏较43岁不OC且最多3周期IVF/PGT-A,平均总成本从62308美元降至30333美元,LB概率从50%升至73%。
- 敏感性分析显示OC在广泛冷冻年龄范围内仍具成本效果。
- 期望1个LB者,32岁前OC获得最高成功概率,39岁前OC仍比IVF/PGT-A更有效;期望2个LB者,31岁前2周期OC获得最高成功概率,39岁前2周期OC仍比IVF/PGT-A更有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost-effectiveness of planned oocyte cryopreservation (OC) as a strategy for delayed childbearing to achieve 1 or 2 live births (LB) compared with in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) at advanced reproductive age. DESIGN: Decision tree model with sensitivity analyses using data from the Society for Assisted Reproductive Technology Clinical Outcome Reporting System and other clinical sources. SETTING: Not applicable. PATIENT(S): A data-driven simulated cohort of patients desiring delayed childbearing with an ideal family size of 1 or 2 LB. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): Probability of achieving ≥1 or 2 LB, average and maximum cost per patient, cost per percentage point increase in chance of LB, and population-level cost/LB. RESULT(S): For those desiring 1 LB, planned OC at age 33 with warming at age 43 decreased the average total cost per patient from $62,308 to $30,333 and increased the likelihood of LB from 50% to 73% when compared with no OC with up to 3 cycles of IVF/PGT-A at age 43. For those desiring 2 LB, 2 cycles of OC at age 33 and warming at age 40 yielded the lowest cost per patient and highest likelihood of achieving 2 LB ($51,250 and 77%, respectively) when compared withpursuing only 1 cycle of OC ($75,373 and 61%, respectively), no OC and IVF/PGT-A with embryo banking ($79,728 and 48%, respectively), or no OC and IVF/PGT-A without embryo banking ($79,057 and 19%, respectively). Sensitivity analyses showed that OC remained cost-effective across a wide range of ages at cryopreservation. For 1 LB, OC achieved the highest likelihood of success when pursued before age 32 and remained more effective than IVF/PGT-A when pursued before age 39, and for 2 LB, 2 cycles of OC achieved the highest likelihood of success when pursued before age 31 and remained more effective than IVF/PGT-A when pursued before age 39. CONCLUSION(S): Among patients planning to postpone childbearing, OC is cost-effective and increases the odds of achieving 1 or 2 LB when compared with IVF/PGT-A at a more advanced reproductive age.
引用
- Bakkensen JB, Flannagan KSJ, Mumford SL, et al. A SART data cost-effectiveness analysis of planned oocyte cryopreservation versus in vitro fertilization with preimplantation genetic testing for aneuploidy considering ideal family size. Fertil Steril. 2022. PMID: 36175208. doi:10.1016/j.fertnstert.2022.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。